Anti-mCTLA4-mIgG2a InvivoFit™
-
Cat.code:
mctla4-mab10-1
- Documents
ABOUT
Anti-mouse CTLA4 antibody for in vivo use
Anti-mCTLA4-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCTLA-4 clone 9D9 [1] and a murine IgG2a constant region. Its sequence is 100% murine (constant and variable regions), ensuring minimal immunogenicity upon repeated injections into mice. This mAb targets murine cytotoxic T-lymphocyte-associated protein 4 (mCTLA-4) and blocks CTLA4-mediated negative signals, downregulating T cell activation. Thus, anti-mCTLA-4 mAb unleashes T cell activity [1, 2].
Notably, the 9D9 mAb, along with the most commercially available anti-mCTLA4 mAbs, features the IgG2b isotype, which displays low antitumor activity in vivo [2]. To overcome this issue, Anti-mCTLA4-mIgG2a InvivoFit™ was generated by recombinant technology and features the murine IgG2a isotype, which mediates potent cytotoxic functions. Anti-mCTLA4-mIgG2a is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.
Key features of Anti-mCTLA4-mIgG2a InvivoFit™:
- Sequence is 100% murine
- Features the IgG2a isotype (associated with high antitumor activity)
- Filter-sterilized (0.2 µm), endotoxin level < 1 EU/mg
- Specifically designed for in vivo studies in mice
- Low aggregation < 5%
- Produced in animal-free facilities and defined media
Anti-mCTLA4-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells, purified by affinity chromatography with protein A, and its binding to mCTLA-4 is validated using ELISA.
This antibody is also available in bulk quantity, please contact us
References:
1. Selby MJ. et al., 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 1(1):32-42.
2. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55.
All products are for research use only, and not for human or veterinary use.
InvivoFit™
InvivoFit™ is a high-quality standard specifically adapted for in vivo studies.
InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay
SPECIFICATIONS
Specifications
CTLA-4, CTLA4, CD152
Mouse
In vivo studies
Sodium phosphate buffer, saccharose
< 5%
0.2 µm filtration
< 1 EU/mg (measurement by kinetic chromogenic LAL assay)
ELISA, in vivo studies
Each lot is tested by ELISA.
CONTENTS
Contents
-
Product:Anti-mCTLA4-mIgG2a InvivoFit™
-
Cat code:mctla4-mab10-1
-
Quantity:1 mg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, also known as CD152) is an inhibitory receptor expressed on activated T lymphocytes. T-cell activation requires two signals. Signal 1 is delivered upon interaction of the T cell receptor (TCR) with antigenic peptides bound to major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). Signal 2 is delivered upon interaction of the co-stimulatory receptor CD28 with the B7 family ligands, B7-1 (CD80) and B7-2 (CD86), on APCs.
CTLA-4 is an immune checkpoint molecule upregulated upon T cell activation. It exerts competitive binding to CD28 ligands, thereby preventing T-cell overstimulation. CTLA-4 blockade with monoclonal antibodies (mAbs) has been used to treat patients with metastatic melanoma.
In vivo Data
In vivo efficacy of InvivoGen’s Anti-mCTLA4-mIgG2a
In vivo efficacy of InvivoGen’s Anti-mCTLA4-mIgG2a
Unlike most immune checkpoint (IC) mAbs on the market, which are produced in hybridomas, InvivoGen’s mouse anti-mouse mAbs are expressed in virus-free CHO cells. This ensures structural stability as well as guaranteeing the highest purity and batch-to-batch consistency; important for mAb efficacy in vivo.
BALB/c mice were challenged with the murine colorectal carcinoma cell line, CT26. After 8 days, treatment was started with InvivoGen's Anti‑mCTLA4‑mIgG2a (recombinant mAb), Competitor X’s Anti‑mCTLA4 (produced in hybridomas; clone 9D9-mIgG2b), or negative controls (saline only and isotype control mAb). Injections were performed twice a week for 3 weeks (a total of 6 times). After 60 days of monitoring, (A) 7/10 mice were tumor-free in the Competitor X mAb-treated group, compared to (B) 9/9 mice tumor-free in the InvivoGen mAb-treated group. Additionally, no significant differences were observed in the health of the mice, with comparable body weight throughout the study (C). Most notably, after 6 injections, 30%* of the mice in the Competitor X mAb-treated group were euthanized due to excessive tumor volume (endpoint criteria), whereas complete tumor regression was observed in all mice in the InvivoGen mAb-treated group (D).
In summary, InvivoGen’s optimized Anti‑mCTLA4‑mIgG2a shows increased in vivo efficiency compared to Competitor X’s mAb, which features the commonly used IgG2b isotype, known to display low antitumor activity in vivo.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz
